Hội chứng Retinoic Acid trong điều trị Lơxêmi cấp tiền tủy bào bằng Atra phối hợp hóa chất

Objective: study on 69 newly diagnosed APL treated with ATRA plus Daunorubicin from 2007 to 2010. Method: 69 newly diagnosed APL patients were admitted to NIHBT during 20072010 period. Regimes used for treatment include ATRA combined Daunorubicin for induction. Result: The incidence of RAS in this study was 31.9 percent. The RAS-related mortality rate was 4.5 percent (1 out of 22 patients). The significant increase of RAS in patients with WBC count greater than 10-109/1 (57.7 percent to 16.3 percent, p0.05), and male (83.3 percent to 46.9 percent, p0,05). Conclusion: The incidence of RAS in this study was 31.9 percent. The initial WBC count greater than 10-109/1, especially in male correlated with an increased risk of developing RAS.